Arthroscopic meniscal procedures are the most commonly performed orthopaedic procedure in the U.S. affecting 15% of Americans ages 10-65 years. Meniscus injury is also known to increase the risk of posttraumatic osteoarthritis (PTOA). The current randomized clinical trial will test a novel intervention after meniscal repair that combines an oral senolytic fisetin and real-time biofeedback program to restore joint loading and subsequent return to activity.

开始日期2025-07-01

申办/合作机构

University of Kentucky

NCT06431932

/ Not yet recruiting临床1/2期IIT

Pharmacokinetics, Safety, and Efficacy of Fisetin - A Phase I and Pilot Phase IIa Study

The accumulation of senescent cells with age is a central mechanism that contributes to the development of chronic diseases, primarily by driving systemic chronic inflammation. Senolytic compounds such as fisetin can selectively target senescent cells for elimination and reduce multiple age-related pathologies in animal models.
We will conduct a clinical trial in healthy volunteers and older patients with multiple chronic diseases. The participants will receive fisetin or placebo for two days, after which they will be examined at regular intervals for up to three months. We will investigate how fisetin is absorbed and metabolized by the body, and whether fisetin is safe. We will also identify methods to best measure the effect of fisetin on chronic inflammation, senescent cells, and general health.

开始日期2025-01-01

申办/合作机构

Hvidovre University Hospital

[+2]

NCT06399809

/ Recruiting临床2期IIT

Fisetin to Reduce Senescence and Mobility Impairment in Peripheral Artery Disease: the FIRST Pilot Randomized Trial

The investigators propose a pilot randomized trial to gather preliminary data to test the hypothesis that Fisetin will reduce abundance of senescent cells in blood, skeletal muscle, and both subcutaneous and inter muscular adipose tissue and improve 6-minute walk distance in 34 people with peripheral artery disease (PAD). the investigators will determine whether greater declines in abundance of cells with senescent markers are associated with greater improvement in 6-minute walk distance in people with peripheral artery disease. In exploratory analyses, the investigators will assess whether Fisetin reduces interleukin-6 (IL-6) and novel senescent markers in adipose tissue, muscle, and/or blood.

开始日期2024-09-30

申办/合作机构

Northwestern University

100 项与漆黄素相关的临床结果

登录后查看更多信息

100 项与漆黄素相关的转化医学

登录后查看更多信息

100 项与漆黄素相关的专利（医药）

登录后查看更多信息

1,666

项与漆黄素相关的文献（医药）

2025-01-01·MATHEMATICAL BIOSCIENCES

Spatio-temporal model of combining chemotherapy with senolytic treatment in lung cancer

Article

作者: Friedman, Avner ; Lazebnik, Teddy

Senescent cells are cells that stop dividing but sustain viability. Cellular senescence is the hallmark of aging, but senescence also appears in cancer, triggered by cells stress, tumor suppression of gene activation, and oncogene activity. In lung cancer, senescent cancer cells secrete VEGF, which initiates a process of angiogenesis, enabling the cancer to grow and proliferate. Chemotherapy kills cancer cells, but some cancer cells become senescent. Hence, a senolytic drug, a drug that eliminates senescent cells, should significantly improve the efficacy of chemotherapy. In this paper, we developed a mathematical spatio-temporal model of combination chemotherapy with senolytic drug in treatment of lung cancer. Model's simulations of tumor volume growth are shown to agree with mouse experiments in the case where cyclophosphamide is combined with the senolytic drug fisetin. It is then shown how the model can be used to assess the benefits of treatments with different combinations and different schedules of the two drugs in order to achieve optimal tumor volume reduction.

2025-01-01·MOLECULAR NEUROBIOLOGY

The Effects of Fisetin and Curcumin on Oxidative Damage Caused by Transition Metals in Neurodegenerative Diseases

Review

作者: Antonyak, Halyna ; Rybak, Oksana ; Dub, Natalia ; Peana, Massimiliano ; Oliinyk, Petro ; Bjørklund, Geir ; Lysiuk, Roman ; Darmohray, Roman ; Antoniv, Olha ; Zayachuk, Vasyl ; Khavrona, Oksana ; Lozynska, Iryna

Neurodegenerative diseases pose a significant health challenge for the elderly. The escalating presence of toxic metals and chemicals in the environment is a potential contributor to central nervous system dysfunction and the onset of neurodegenerative conditions. Transition metals play a crucial role in various pathophysiological mechanisms associated with prevalent neurodegenerative diseases such as Alzheimer's and Parkinson's. Given the ubiquitous exposure to metals from diverse sources in everyday life, the workplace, and the environment, most of the population faces regular contact with different forms of these metals. Disturbances in the levels and homeostasis of certain transition metals are closely linked to the manifestation of neurodegenerative disorders. Oxidative damage further exacerbates the progression of neurological consequences. Presently, there exists no curative therapy for individuals afflicted by neurodegenerative diseases, with treatment approaches primarily focusing on alleviating pathological symptoms. Within the realm of biologically active compounds derived from plants, flavonoids and curcuminoids stand out for their extensively documented antioxidant, antiplatelet, and neuroprotective properties. The utilization of these compounds holds the potential to formulate highly effective therapeutic strategies for managing neurodegenerative diseases. This review provides a comprehensive overview of the impact of abnormal metal levels, particularly copper, iron, and zinc, on the initiation and progression of neurodegenerative diseases. Additionally, it aims to elucidate the potential of fisetin and curcumin to inhibit or decelerate the neurodegenerative process.

2025-01-01·ULTRASONICS SONOCHEMISTRY

An ultrasonic degraded polysaccharide extracted from Pueraria lobata ameliorate ischemic brain injury in mice by regulating the gut microbiota and LPS-TLR4 pathway

Article

作者: Dou, Zuman ; Zhang, Huaying ; Zhu, Qingfeng ; Zhang, Wenyang ; Wang, Qian ; Zuo, Xiangyu ; Xiao, Yu ; Chen, Xiaoxia ; Zhang, Yulong ; Zhou, Hongwei ; Li, Zhixin ; Li, Zhuang ; Zhang, Lingling ; Duan, Qingfei ; Niu, Hui ; Zeng, Shanshui ; Li, Shanshan

Ischemia brain injury is closely associated with the gut microbiota. Polysaccharides, as a typical prebiotic, have been extensively employed in stroke treatment. In our previous study, Pueraria lobata polysaccharide (PLP-3) with antioxidant activity was prepared via water extraction and alcohol precipitation combined with ultrasonic degradation. In this study, the effects of PLP-3 on ischemia brain injury and its regulatory effects on the gut microbiota were further investigated. The results demonstrated that PLP-3 effectively reduced the infarct area, improves neurological function, and alleviates neuronal damage of cerebral ischemia injury. Mechanistically, PLP-3 significantly reduces serum LPS levels in MCAO mice, inhibiting TLR-4 activation in brain tissue and thereby reducing IL-1β and TNF-α levels. Meanwhile, PLP-3 significantly repaired the intestinal barrier injury by increasing the expression of tight junction proteins (ZO-1 and Occludin) and increasing the number of goblet cells. Additionally, the structure and composition of gut microbiota in MCAO mice after PLP-3 intervention, were also significantly changed, especially the enrichment of Lactobacillus and the reduction of Corynebacterium and Staphylococcus. At the same time, short chain fatty acid, metabolites of gut microbiota, were also significantly increased and significantly correlated with the abundance of Lactobacillus. Moreover, LC-MS untargeted metabolomics revealed that PLP-3 significantly improves the intestinal metabolic profile after cerebral ischemia injury, upregulating the amino acid biosynthesis pathway and enriching amino acids such as glutamine and arginine, as well as neuroprotective flavonoids such as fisetin and liquiritigenin. These results suggested that PLP-3 could protect mice from cerebral ischemia-reperfusion injury by regulating gut microbiota and repairing gut barrier, inhibiting brain LPS/TLR4/MyD88 inflammatory pathway, therefore we provide a theoretical basis for PLP-3 as a functional food to prevent ischemic brain injury.

项与漆黄素相关的新闻（医药）

2025-01-09

·Business Wire

Bonerge Announces the New 108 Person Clinical Trial: Exploring Skin and Organ Anti-Aging Innovations

NEW YORK--( BUSINESS WIRE )--Bonerge announced the initiation of its clinical trial, focusing on Fisetin, Urolithin A, and Ergothioneine. Involving 108 participants, this trial aims to evaluate their combined effects on skin health and organ rejuvenation when taking orally, providing more reliable options for the market. Senolytics Research: Advancing the Science of Anti-Aging In recent years, Senolytics research has advanced rapidly, with institutions like the Mayo Clinic and Wake Forest University at the forefront. Despite fruitful research, identifying optimal applications to translate Senolytics into market solutions remains crucial. In October 2024, the Mayo Clinic published groundbreaking findings in Nature Aging, identifying 67 plasma proteins, with IL-23R emerging as a promising anti-aging biomarker 1 . The study explored various promising Senolytics, including Fisetin, demonstrating a positive response in reducing senescence-related proteins and indicating potential for organ rejuvenation via senescent cell clearance 2 . The concept of organ rejuvenation offering deeper insights into its systemic effects and guiding anti-aging strategies. Senolytics show strong potential for organ rejuvenation applications and promise broader future prospects. Bonerge’s Clinical Trial: Exploring Skin as the Key to Rejuvenation The skin, the largest organ of the human body, is the most visible indicator of aging and a key target for anti-aging. Bonerge has launched a clinical trial focused on skin anti-aging, involving 108 participants. The trial evaluates skin anti-aging effects by assessing factors like skin heme, skin inflammation, transepidermal water loss, wrinkles, skin elasticity, skin firmness, melanin levels, and skin tone. Spanning 56 days, it aligns with two skin regeneration cycles, providing a detailed analysis of these key skin health indicators. Three ingredients tested in the trail: Fisetin: Among natural ingredients, fisetin has the strongest activity in clearing senescent cells. Its core mechanism promotes apoptosis of senescent cells and reduces SASP (Senescence-Associated Secretory Phenotype) secretion, alleviating chronic inflammation and combating inflammaging 3 , contributing to organ rejuvenation. Urolithin A: A rising star in nutritional supplements, Urolithin A has shown significant anti-photoaging effects. Photoaging, primarily caused by UVA (ultraviolet A) radiation, accelerates skin aging. Urolithin A helps protect skin by reducing the senescent phenotype of skin fibroblasts triggered by UVA, lowering intracellular ROS (reactive oxygen species), and activating antioxidant enzymes. These actions collectively support skin health and combat the harmful effects of photoaging 4 . Ergothioneine : Currently recognized as the only antioxidant that targets mitochondria, it reduces oxidative damage within mitochondria, supporting energy production and potentially preventing cellular aging 5 . Key Focus: Exploring Individual Ingredients and Combined Synergies In this clinical trial, while examining the skin anti-aging effects of individual ingredients, the combination of the three ingredients have also been tested to explore the synergistic effects on skin health and anti-aging. Path Ahead: Trial Progress and Future Expectations The clinical trial is progressing as planned and is expected to conclude in March 2025. Bonerge is hopeful that this study will provide valuable evidence for the anti-aging market, paving the way for the application of Senolytics in skin health and broader anti-aging treatments. References [1] Chase M. Carver, et al. IL-23R is a senescence-linked circulating and tissue biomarker of aging. Nature Aging, Dec 2024. [2] Researchers discover an aging and inflammation biomarker - Mayo Clinic News Network [3] Matthew J. et al. Fisetin is a senotherapeutic that extends health and lifespan. EBioMedicine 36 (2018). [4] Wenjie Liu , et al. Urolithin A protects human dermal fibroblasts from UVA-induced photoaging through NRF2 activation and mitophagy. J Photochem Photobiol B. 2022 Jul. [5] Brown, Lisa, et al. L-Ergothioneine and Its Protective Role in Cellular Health. Journal of Clinical Nutrition, vol 56.

临床研究

2024-12-31

·Business Wire

BeFisetin® is Gaining the First Fisetin Ingredient SA-GRAS Certification

NEW YORK--( BUSINESS WIRE )--In 2024, Bonerge's premium fisetin branded ingredient, BeFisetin®, initiated the SA-GRAS (Self-Affirmed Generally Recognized As Safe) certification process, with completion expected in February 2025. This certification underscores Bonerge's unwavering commitment to product safety, quality control and serves as a key milestone in its expansion into the global fisetin market. Fisetin: The Anti-aging Potential of Natural Polyphenols Fisetin is a natural polyphenol widely present in various fruits and vegetables such as strawberries, apples, and persimmons. In recent years, the scientific community's enthusiasm for exploring fisetin has been continuously rising. Numerous research findings have revealed that fisetin has unique biological properties in reducing inflammatory factors, strengthening cell health, and delaying aging [1-3], and its related applications have also attracted extensive and in-depth attention. Biochemical studies have shown that fisetin can exert its effects through multiple mechanisms. It can effectively reduce senescent cells in the brain, skin, and various organs, regulate inflammatory factors, and scavenge free radicals [4]. This makes fisetin an attractive dietary supplement, showing broad application prospects in healthy aging and long-term health management. BeFisetin®: Marketing Strategy and Innovation As a company dedicated to the development and research of high-quality ingredients, Bonerge recognizes the growing global demand for safe and effective dietary supplements. It is Bonerge’s principle to leverage cutting-edge science to transform advanced research into practical health solutions. Bonerge is continuously improving the purity and bioavailability of BeFisetin®, while integrating sustainable production practice, demonstrating a strong commitment to environmental responsibility. Focusing on the great potential of fisetin, Bonerge has engaged in in-depth strategic collaborations with multiple research institutions and universities to strengthen the scientific validation and credibility of BeFisetin®, continuously enhancing its trust and reputation through rigorous scientific verification. This ensures consumers have access to transparent, reliable health solutions. SA-GRAS Certification: An Extended Standard in Safety and Trust SA-GRAS certification, a critical extension of the FDA's GRAS framework, allows companies to confirm the safety of their products through rigorous self-assessment. This process involves establishing stringent product standards, conducting comprehensive toxicity and safety evaluations, and systematically assessing raw materials, manufacturing processes, and product stability. Companies need to work with independent professional organizations to prepare detailed safety assessment reports, which are reviewed by an expert panel. The rigorous certification process drives Bonerge to further optimize its product quality systems and elevated BeFisetin®'s competitiveness in the global market. For Bonerge, SA-GRAS certification is not merely a regulatory milestone but a testament to its relentless pursuit of product excellence and its commitment to consumer safety. Looking Ahead: Responsibility and Opportunity The expansion of aging population is a global challenge, driving increasing demand for health-focused anti-aging solutions. Bonerge is committed to leveraging BeFisetin®'s superior quality to advance scientific research, foster innovation, and provide consumers with safer and trustworthy products. To be or not to be, that is the question! BeFisetin®: A scientific breakthrough as the world’s first SA-GRAS-certified fisetin ingredient, setting a new industry standard. References [1] Yoon S, Lee H, Kim J, et al. A natural flavonoid, fisetin, alleviates neuroinflammation and memory impairment in D-galactose-treated mice[J]. Frontiers in Pharmacology, 2023, 14: 1134733. [2] Li X, Zhang H, Guo Y, et al. Fisetin promotes osteoblastogenesis and inhibits adipogenesis in bone marrow stromal cells through the activation of the Wnt/β-catenin pathway[J]. International Journal of Molecular Sciences, 2019, 20(23): 5957. [3] Yousefzadeh MJ, Zhu Y, McGowan SJ, et al. Fisetin is a senotherapeutic that extends health and lifespan[J]. EBioMedicine, 2018, 36: 18-28. [4] Takaya K, Kawaguchi M, Mizutani K, et al. Fisetin, a potential skin rejuvenation drug that eliminates senescent cells in the dermis[J]. Biogerontology, 2023, 24(5): 409-421.

2024-12-17

·生物世界

Nature Aging：梅奥医学中心发现新型衰老标志物——IL-23R

撰文丨王聪编辑丨王多鱼排版丨水成文细胞衰老是一种以细胞周期停滞和衰老相关分泌表型（SASP）为特征的衰老机制。临床前研究表明，靶向衰老细胞生存通路的抗衰老药物可对抗多个器官的年龄相关疾病。尚未有任何研究证实不同类型的衰老细胞清除药物在体内对改变衰老和衰老标志物的相对有效性。 2024年12月10日，梅奥医学中心的研究人员在 Nature Aging 期刊发表了题为：IL-23R is a senescence-linked circulating and tissue biomarker of aging 的研究论文。该研究表明，白细胞介素-23受体（IL-23R）是一种衰老相关的循环和组织生物标志物。细胞衰老是一种年龄相关机制，参与多种器官系统的发病，包括免疫功能障碍、心血管和代谢性疾病、肺纤维化、骨质疏松、肾脏疾病、肝损伤、肌肉减少症和认知功能下降等。衰老血液中的因子可驱动许多组织的衰老和炎症激活。但早衰循环因子的组织和细胞特异性起源尚未明确。来源于衰老细胞的循环蛋白可能反映全身衰老细胞负荷，可能被开发为诊断或预后生物标志物，并且可能是早衰器官间通讯的介质。在这项最新研究中，研究团队建立了衰老和衰老相关的血浆蛋白和组织转录物，它们在老年和年轻的小鼠中发生了变化。研究团队在老年p16-InkAttac小鼠中研究了Venetoclax（一种Bcl-2抑制剂）、Navitoclax（一种Bcl-2抑制剂）、fisetin（漆黄素）或luteolin（木犀草素）急性治疗与转基因衰老细胞清除之间的反应。结果显示，年龄依赖性的血浆蛋白变化，包括IL-23R、CCL5和CA13，被治疗药物逆转，这对应于组织的表达差异，特别是在肾脏。而在人的一生中，血浆中IL-23R随着年龄的增长而增加。这些结果揭示了循环因子作为与衰老相关的器官间信号转导的候选介质和全身衰老细胞负荷的生物标志物。论文链接： https://www.nature.com/articles/s43587-024-00752-7 设置星标，不错过精彩推文开放转载欢迎转发到朋友圈和微信群微信加群为促进前沿研究的传播和交流，我们组建了多个专业交流群，长按下方二维码，即可添加小编微信进群，由于申请人数较多，添加微信时请备注：学校/专业/姓名，如果是PI/教授，还请注明。点在看，传递你的品味

100 项与漆黄素相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
-	-	-	DB07795

研发状态

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
腕管综合征	临床2期	美国	Mayo Clinic	2022-10-09
炎症	临床2期	美国	Mayo Clinic	2020-08-03
新冠肺炎后遗症	临床2期	美国	Mayo Clinic	2020-08-03
肾纤维化	临床前	中国	四川大学华西医院（四川省国际医院）	2023-03-01
黑色素瘤	临床前	美国	University of Wisconsin Madison	2013-04-15
前列腺癌	临床前	美国	University of Wisconsin Madison	2009-05-01
结肠癌	临床前	美国	University of Wisconsin Madison	2008-05-01

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT04771611 (COVFIS-HOME, CTgov)	临床2期	新型冠状病毒感染	55	Fisetin (Treatment Group)	鬱憲願遞範鹹壓鏇鏇觸(襯簾鑰構齋醖憲築鏇襯) = 憲簾鑰齋餘鹹憲願艱艱遞廠築獵衊願憲鑰鏇淵 (夢繭觸遞淵餘鹹齋範齋, 繭膚構鏇鑰鏇願範夢鑰 ~ 選窪顧範餘鏇蓋製鬱觸) 更多	-	2023-08-01
				Placebo (Placebo)	鬱憲願遞範鹹壓鏇鏇觸(襯簾鑰構齋醖憲築鏇襯) = 夢糧壓餘衊餘鹽鏇願壓遞廠築獵衊願憲鑰鏇淵 (夢繭觸遞淵餘鹹齋範齋, 網遞糧糧夢鹹餘觸築獵 ~ 製鹹獵繭鹽糧願繭夢憲) 更多